ADC TOXICITY ATLAS
AtlasPayloads and LinkersPayloadsTargetsMethods
← Atlas

SC-011 / ABBV-011 (SC17, SEZ6, calicheamicin)

Discontinued
SC-011; SC011; ABBV011; ABBV 011
Sponsor
AbbVie (originated Stemcentrx)
Indication
Relapsed/refractory small cell lung cancer (SCLC)
Target family
Other
RP2D dose
1.0 mg/kg
Every 3 weeks (Q3W)RP2D
01
Multi-organ toxicity

Fingerprint & organ drill-down

Also reported
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed
1 adverse-event term

Ocular

Any-grade
0%
G3+
0%
RP2D
sagittal schematic · Unknown
↳

Tissues shaded by reported adverse-event rate.

Cornea
AE
-
Express.
-
Limbus
AE
-
Express.
-
Conjunctiva
AE
-
Express.
-
Lens
AE
-
Express.
-
Retina / RPE
AE
-
Express.
-
Dominant tissue
None
Surface subtype
None
Reversibility
Unknown
Reported ocular events
Any eye toxicity (explicitly assessed, none reported)0%
n=99
02
Construct

Molecular anatomy

Antibody
IgG1
Humanized
Linker
Disulfide
Non-cleavable
2
DAR
Payload
N-acetyl-gamma-calicheamicin
DNA double-strand break induction (enediyne DNA-damaging agent)
Linker structureC26H45N3O11
NCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCC1C(=O)C=CC1=O
Payload structureC57H76IN3O22S4
CCN([C@H]1CO[C@H](C[C@@H]1OC)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3C#C/C=C\C#C[C@@]4(CC(=O)C(=C3C4=CCSSSC)NC(=O)OC)O)C)NO[C@H]5C[C@@H]([C@@H]([C@H](O5)C)SC(=O)C6=C(C(=C(C(=C6OC)OC)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)OC)O)I)C)O)O)C(=O)C
03
Antibody

Antibody & Fc engineering

Antibody
SC17
Isotype
IgG1
Origin
Humanized
Fc modifications
-
Glycoengineering
-
Effector silencing
Not reported (IgG1 backbone; no explicit Fc-silencing described)
FcγR binding
Retained
C1q binding
Unknown
04
Linker & conjugation

Linker chemistry

Linker profile
Linker
LD19.10 (Mc-PEG8 hindered-disulfide linker)
Class
Disulfide
Cleavage
Non-cleavable
Attachment
Site-specific (engineered Cys)
Conjugation
Site-specific cysteine conjugation
Symmetry
Site-specific (paired)
DAR (mean)
2
DAR homogeneity
Homogeneous
Plasma t½
-
Cleavage trigger
Non-cleavable; payload released via reduction of hindered disulfide (LD19.10), before or after antibody catabolism
Release control
N/A
Hydrophilicity mask
Discrete-PEG-spacer
Formula
C26H45N3O11
Linker MW
575.656 Da
Linker TPSA
182.97 Ų
Linker xLogP
-1.2543
ADCdb linker
LIN0KQAXA
In-vitro stability
-
05
Payload

Payload & physicochemistry

Payload profile
Payload
N-acetyl-gamma-calicheamicin
Class
Calicheamicin
Mechanism
DNA double-strand break induction (enediyne DNA-damaging agent)
Released catabolite
N-acetyl-gamma-calicheamicin (active enediyne warhead)
Mechanistic subtype
DNA-strand-break
Stereochem / salt
-
Bystander
Partial
PAMPA rank
-
MW
1410.4 Da
XLogP3
2
logD₇.₄
-
TPSA
418 Ų
pKa
-
Charge pH 7.4
0
H-bond donors
7
H-bond acceptors
27
IC50 (HCEC)
-
Formula
C57H76IN3O22S4
PubChem CID
134819845
ADCdb payload
PAY0GKVJX
Bioactivity note
ADCdb payload page (PAY0GKVJX) reports payload potency IC50 = 112 pmol/L (0.112 nM) in HEK-293T cells. Payload mechanism: enediyne that, after trisulfide reduction/Bergman-type cyclization, generates a diradical inducing DNA double-strand breaks.
06
Dosing & regimen

Dosing

RP2D dose
1.0 mg/kg
Schedule
Every 3 weeks (Q3W)
Route
IV
Fractionated
No
n at RP2D
40
Dose basis
TBW
Trial phase
Phase 1
Dose-OAE available
Yes
Tox summary basis
RP2D
07
Ocular & expression

Ocular profile & eye-tissue target expression

Target profile
OAE any-grade
0 %
OAE grade 3+
0 %
OAE data status
documented-absent
Severity (weighted)
0
Keratopathy
-
Conjunctival
-
Dry eye
-
Blurred vision
-
Dominant tissue
None
Surface subtype
None
Grading scale
CTCAE v5
Reversibility
Unknown
Target expression in eye tissues (HCA detection · HPA bulk)
Cornea (central)
-
Cornea (limbal)
-
Conjunctiva
-
RPE
-
Retina (HPA)
-
Cross-trial comparability
Ascertainment: Symptom-driven reportingScale: CTCAE v5Denominator: RP2D⚠ OAE rate not directly comparable across trials
08
Identity & registry

Identifiers, registry & notes

ADC id
abbv-011
Approval status
Discontinued
Approval year
-
UniProt
Q53EL9
ADCdb ADC
DRG0HEJWD
ADCdb antibody
ANI0PWRSL
ADCdb target
TAR0RIOXT
Primary source
Morgensztern et al., Clin Cancer Res 2024;30(22):5042 (PMC11565168)
Aliases & development codes
SC-011; SC011; ABBV011; ABBV 011
Notes
SEZ6-targeting calicheamicin ADC for R/R SCLC; Phase 1 program terminated. Ocular finding is an explicit documented zero: "no eye toxicities of any grade related to ABBV-011 treatment were reported" and "no on-target neurologic or ocular toxicities" (Morgensztern et al. CCR 2024; CTCAE v5.0). Useful low/control case. NOTE on linker cleavage: ADCdb names the linker "Mc-PEG8-acid-labile linker" (LIN0KQAXA), but the primary literature (Mol Cancer Ther 2022, PMC9381089; clinical CCR 2024) describes the linker drug as LD19.10, a NON-cleavable linker that releases payload only upon reduction of a hindered disulfide (before/after antibody degradation), with maleimide (Mc) attachment and a PEG8 spacer. I report cleavage as non-cleavable per primary lit. NOTE on conjugation: ADCdb lists "Random Cysteines," but primary lit (PMC9381089) states site-specific cysteine conjugation at DAR=2 on a cysteine-engineered humanized IgG1 (SC17); I report site-specific cysteine, DAR 2. Linker physchem values (SMILES/formula/MW/TPSA/xLogP) are ADCdb's for the Mc-PEG8 linker fragment.